AFT new FDA approval could be a shot in the arm

AFT new FDA approval could be a shot in the arm
Analyst sentiment is positive after FDA approval of Maxigesic IV. (Image: Hyloris Pharmaceuticals)
Ben Moore
AFT Pharmaceuticals had a bump in share price on Wednesday morning following approval of its intravenous post-operative pain relief drug by the United States Food and Drug Administration.Following the announcement of the approval of Maxigesic IV, which came in overnight, the stock lifted 16 cents per share to $3.56 at the open on the New Zealand stock exchange (NZX), up from $3.40 at yesterday's close. It has since dipped to $3.50.AFT co-founder and managing director Hartley Atkinson said they were delighted to receive the second appro...

More Markets

Ousted Rakon director could pocket takeover windfall
Markets

Ousted Rakon director could pocket takeover windfall

Jon Raby couldn't get elected to the Rakon board but snapped up some shares anyway.

Brokers reveal top NZX picks for 2026
Markets

Brokers reveal top NZX picks for 2026

Billions shifting from term deposits could boost NZX heavyweights and recovery plays.

Why Rakon’s $390m takeover failed
Markets Best of BusinessDesk

Why Rakon’s $390m takeover failed

The Skyworks deal collapsed in 2024. Now, another deal is on the table.

Business confidence boost uninspired NZ sharemarket
Markets Market Close

Business confidence boost uninspired NZ sharemarket

The S&P/NZX 50 Index closed at 13,656.05, down 27.24 points or 0.2%.

Graham Skellern 13 Jan 2026